JPMorgan Chase & Co. Cuts Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target to $36.00
Day One Biopharmaceuticals (NASDAQ:DAWN – Free Report) had its price objective decreased by JPMorgan Chase & Co. from $38.00 to $36.00 in a research note issued to investors on Tuesday morning, Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock. DAWN has been the subject of a number of other […]
More Stories
Lennar (NYSE:LEN) Issues Quarterly Earnings Results, Beats Estimates By $0.28 EPS
Lennar (NYSE:LEN – Get Free Report) posted its quarterly earnings results on Thursday. The construction company reported $3.90 earnings per...
Secret Service, Homeland Security Sued Over Records Related to Trump Assassination Attempt
By Jack Phillips A lawsuit was filed against the U.S. Secret Service and Department of Homeland Security (DHS) in a...
Trump Proposes Temporary 10 Percent Cap on Credit Card Interest Rates
By Andrew Moran Former President Donald Trump has proposed a 10 percent temporary cap on credit card interest rates, which...
A Particular Bacteria in Your Urine Can Help Protect Against Kidney Stones
By Rachel Ann T. Melegrito The urinary tract microbiome, also known as the urobiome, is home to various microorganisms. Researchers...
Cracker Barrel Old Country Store (NASDAQ:CBRL) Announces Earnings Results
Cracker Barrel Old Country Store (NASDAQ:CBRL – Get Free Report) released its quarterly earnings data on Thursday. The restaurant operator...
FedEx (NYSE:FDX) Posts Earnings Results, Misses Estimates By $1.22 EPS
FedEx (NYSE:FDX – Get Free Report) released its quarterly earnings data on Thursday. The shipping service provider reported $3.60 EPS...